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Background: Owing to its large molecular size, polyethylene glycol (PEG)-precipitable thyrotropin (TSH) can accumulate in the 
circulation, elevating TSH levels. PEG-precipitable TSH can be used to detect macro-TSH (mTSH) in serum. Our aim was to evalu-
ate the prevalence of mTSH in patients who had undergone thyroidectomy for thyroid cancer.
Methods: Seventy-three thyroid cancer patients and 24 control subjects on levothyroxine (LT4) TSH-suppressive or replacement 
therapy were evaluated. Screening for mTSH was performed by adding PEG to serum in order to precipitate γ-globulin. A percent-
age of PEG-precipitable TSH ≥80% was considered suggestive of mTSH. 
Results: No correlation between free-T4 (fT4) and TSH levels was found. PEG-precipitable TSH was 39.3%±1.9% in thyroid can-
cer patients and 44.1%±3.9% in controls. Macro-TSH was deemed to be present in one thyroid cancer patient and in two control 
subjects. Only in the thyroid cancer group was PEG-precipitable TSH found to be negatively correlated with fT4 concentration. No 
correlation was found between PEG-precipitable TSH and other clinical conditions in any patients. 
Conclusion: The presence of mTSH seems to be a rare phenomenon in thyroid cancer. In some patients with low PEG-precipitable 
TSH, a reduction in LT4 dosage could be suggested. LT4 dosage adjusted to body weight is the main factor in maintaining TSH in a 
semi-suppressed or normal range. Evaluation of mTSH could be necessary in patients in whom a balance is required between ade-
quate TSH suppression and the avoidance of unnecessary exogenous hyperthyroxinemia.
Keywords: Polyethylene glycol-precipitable thyrotropin; Macro-thyrotropin; Thyrotropin; Levothyroxine-posology; Thyroid neo-
plasms 
INTRODUCTION
After primary therapies, adherence to follow-up examinations 
and the optimization of thyrotropin (TSH)-suppressive therapy 
with levothyroxine (LT4), respectively, contribute to ruling out 
tumor recurrence and improving quality of life. According to re-
cent guidelines, LT4 dosage in thyroid cancer is age-, tumor 
stage-, and histology-dependent [1]. Therefore, the balance be-
tween necessary and unnecessary exogenous hyperthyroxin-
emia should always be considered in the management of thyroid 
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cancer patients [2]. 
It is well known that that about 40% of patients taking LT4 
for benign [3] or malignant [4,5] thyroid pathologies do not 
have serum TSH in the adequate range, and the risk of iatrogen-
ic hypothyroxinemia and hyperthyroxinemia is always possible 
[2,4-6]. The main causes of inappropriately high TSH levels are 
low LT4 dosages for body-weight and composition [7], drugs 
and foods which interfere with LT4 absorption [5,8], common 
gastrointestinal disorders [8], bariatric surgery [9], and pregnan-
cy [10]. Rarer causes of increased TSH that mimic subclinical 
hypothyroidism are human anti-mouse antibodies that interfere 
with immunoassay systems [11] and the macro-molecular com-
plex of TSH and anti-TSH immunoglobulin (macro-TSH 
[mTSH]) [12]. 
Macro-TSH displays a large molecular size on gel filtration 
chromatography (>150 kDa), and has been described in several 
case reports in recent years [13-15]. As in the case of macro-
prolactin [16], the bioactivity of mTSH may be low, and mTSH 
may accumulate in the circulation, causing spurious elevated 
TSH levels [13-16]. More recent papers from Hattori et al. [17-
19] reported that (1) mTSH exhibited laboratory features similar 
to those of subclinical hypothyroidism [17]; (2) that there were 
no commercial TSH immunoassay platforms that do not cross 
with mTSH [18]; and (3) that mTSH may persist in patients for 
a long time [19]. According to these authors, the incidence of 
subclinical hypothyroidism might be overestimated, owing to 
the presence of mTSH in sera, and screening for mTSH should 
be performed before hormone replacement therapy is initiated 
in subclinical hypothyroidism [17].
To our knowledge, studies on mTSH in other cohorts of pa-
tients are lacking. Recently, Kadoya et al. [20] reported that an 
increase in serum mTSH is associated with poor sleep quality in 
patients with cardiovascular risk factors and, surprisingly, that 
mTSH is present even in patients with normal TSH levels and is 
regulated by different mechanisms from those regulating free-
TSH. No data are available in patients with a history of thyroid 
carcinomas, in whom LT4 therapy must be carefully tailored in 
order to prevent under-treatment or unnecessary over-treatment. 
The aim of our single-center study was to evaluate the preva-
lence of mTSH in a cohort of patients who had undergone thy-
roidectomy for thyroid cancer and, as a control group, in pa-
tients who had undergone surgery for benign thyroid pathology. 
As stated by Hattori et al. [17] with regard to subclinical hypo-
thyroidism, our main interest was to determine whether, in pa-
tients on chronic LT4 therapy, mTSH screening may be justified 
when higher than expected LT4 dosages are needed in order to 
achieve the therapeutic target of serum TSH. 
METHODS
Outpatients with a history of thyroid cancer (study group) and 
outpatients with post-surgical thyroidectomy for benign pathol-
ogy (control group), over 18 years of age, were recruited in 
2016 for the study of mTSH during their annual follow-up ex-
amination at our Thyroid Cancer Unit. Written informed con-
sent to participate in the study was obtained from all patients. 
Data from 73 study group patients and 24 control group patients 
were evaluated. All subjects were on chronic LT4 treatment in 
order to reach age- and risk-adjusted TSH levels in the study 
group and to control post-surgical hypothyroidism in the control 
group. Brand LT4 in various formulations (tablets, soft gel, liq-
uid solution) was taken on waking, in a fasting condition, 30 
minutes before breakfast [5]. Some clinical data are reported in 
Table 1. The majority of thyroid cancers were papillary thyroid 
Table 1. Clinical Data of Study and Control Group Subjects




Age, yr 61.9±13.9 63.5±11.2 0.551
Sex, female/male 57/16 (78.1/21.9) 19/5 (79.2/20.8) 1.000 
Years after surgery 11.1±1.0 6.0±1.0 0.002
Thyroid cancer histology
   PTC 62 (84.9) -
   FvPTC 5 (6.9) -
   FTC 2 (2.7) -
   MTC 4 (5.5) -
AJCC stage on diagnosis
   Stage 1 55 (75.3) -
   Stage 2 7 (9.6) -
   Stage 3 9 (12.3) -
   Stage 4 1 (1.4) -
   Unknown 1 (1.4) -
Radioiodine ablation 47 (64.4) -
LT4, µg/kg b.w. 1.57±0.04 1.37±0.08 0.005
fT4, pmol/L 20.3±0.4 20.5±0.5 0.869
TSH, mIU/L 1.08±0.16 1.64±0.28 0.005
Values are expressed as mean±SEM or number (%). Tumor staging 
was done according to the American Joint Committee on Cancer 
(AJCC) 7th edition, AJCC.
PTC, papillary thyroid cancer; FvPTC, follicular variant of PTC; FTC, 
follicular thyroid carcinoma; MTC, medullary thyroid carcinoma; LT4, 
levothyroxine; b.w., body weight; fT4, free-T4; TSH, thyrotropin. 
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cancer (85% of total) with a low-risk stage on diagnosis. Total 
thyroidectomy was the primary treatment in all but five thyroid 
cancer patients (93%) and in all but three control subjects 
(88%). Ablative radioiodine therapy was undertaken in 67% of 
patients with thyroid cancer of follicular origin. At the time of 
the study, positive thyroid autoantibodies were found in two 
study group patients and one control group patient. In all but 
three cases (two medullary thyroid carcinomas; one papillary 
thyroid carcinoma) calcitonin (Ct) or thyroglobulin (Tg) levels 
were indicative of cure (96%). Patients who had undergone 
more conservative treatments were regarded as cured on the ba-
sis of more than 5 years’ stability of their clinical and biochemi-
cal status. 
Clinical examination comprised neck sonography, body 
weight (b.w.) evaluation, and pharmacological anamnesis. At 
the time of examination, which was performed between 2:00 
PM and 4:00 PM, blood samples for the study were drawn. 
Free-T4 (fT4) and TSH levels were evaluated by means of elec-
tro-chemiluminescence immunoassays. Methods were opti-
mized on an automated analytic platform (Cobas c701, Roche 
Diagnostics, Mannheim, Germany). Normal ranges are 12.0 to 
22.0 pmol/L for fT4 and 0.3 to 4.2 mIU/L for TSH. The func-
tional sensitivity of the TSH assay is 0.03 mIU/L, with intra- 
and inter-assay coefficients of variation of 3% and 7%, respec-
tively. Tg and anti-Tg antibody (TgAb) were evaluated as previ-
ously reported [5]. Serum Ct was assayed by means of chemilu-
minescence immunoassay (Dia Sorin, Saluggia, Italy); in our 
laboratory the upper limit of the normal Ct range is 10 ng/L.
Macro-TSH was screened by adding polyethylene glycol 
(PEG, 25%; 0.2 mL) to serum (0.2 mL) in order to precipitate 
γ-globulin fractions. The values of TSH in the supernatant and 
1:2 diluted sera were used for the analysis. In accordance with 
the method of Hattori et al. [17-19], the PEG-precipitable TSH 
(%), which represents the concentration of mTSH, was calculat-
ed as follows: (serum TSH–TSH recovered after PEG)/serum 
TSH×100. Arbitrarily, a PEG-precipitable TSH (%) value ≥
80% was considered suggestive of mTSH in serum.
GraphPad version 6.0 software (GraphPad, San Diego, CA, 
USA) was used for statistical analysis. To compare continuous 
data, the Mann-Whitney test was used. Percentages were com-
pared by means of Fisher exact test. Correlations were evaluated 
by means of the Spearman test. Data are reported as mean±
standard error of mean (SEM) if not otherwise reported. Signifi-
cance was set at P≤0.05. Data collection and subsequent analy-
sis were performed in compliance with the Helsinki Declaration 
and approved by the University of Genoa Ethics Committee.
RESULTS
The study and control groups were similar in age and male/fe-
male distribution. The length of time since surgery was signifi-
cantly greater in the study group than in the control group 
(P=0.002). In keeping with the histological diagnosis, the dos-
age of LT4 therapy was slightly but significantly higher and 
TSH levels were slightly but significantly lower (P=0.005 for 
both) in the study group than in controls (Table 1). No correla-
tion between fT4 and TSH levels was found in either group 
(Fig. 1). Only few subjects showed inadequate TSH levels for 
their clinical condition (study group, 12%; control group, 8%). 
Fig. 2 reports the distribution of PEG-precipitable TSH (%) val-
ues in both groups. In both groups, mTSH showed a normal dis-
tribution, ranging from 0% to 92%. On average, PEG-precipita-
ble TSH was 39.3%±1.9% in the study group and 44.1%±
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Fig. 1. Correlation between free-T4 (fT4) and thyrotropin (TSH) levels in (A) study (n=73; Spearman correlation coefficient [Sr], –0.20; 
P=0.09) and (B) control (n=24; Sr, –0.20; P=0.35) groups. 
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criteria, mTSH was deemed to be present in one female patient 
(75 years old) with a history of low-risk papillary thyroid carci-
noma, who was on 1.3 µg/kg b.w. of LT4 to maintain TSH at a 
level of 1.77 mIU/L. This patient had undergone surgery alone 
2 years earlier; we increased the dosage of LT4 to 1.5 µg/kg b.w. 
in order to maintain TSH levels in the 0.55 to 0.69 mIU/L range. 
In this patient, hypertension was the only other medical com-
plaint. In two control subjects (one 60-year-old female and one 
67-year-old male) with mTSH, thyroidectomy had been per-
formed 5 and 2 years earlier for a follicular nodule and for la-
ryngeal cancer, respectively. LT4 was administered at a dosage 
of 1.3 and 1.4 µg/kg b.w., respectively, and TSH levels were 
0.47 and 0.30 mIU/L. The male control had hyperthyroxinemia 
(fT4, 25.3 pmol/L), while in the female control fT4 was 17.9 
pmol/L. In both subjects, anti-hypertensive therapies were on-
going; the male was also taking calcium carbonate, which can 
interfere with LT4 absorption. In both subjects, a few adjust-
ments to LT4 dosage were made in order to maintain TSH lev-
els in the 0.31 to 0.94 mIU/L to 0.30 to 0.90 mIU/L ranges, re-
spectively. In all subjects with a suspected history of mTSH, 
laboratory data were negative for rheumatoid arthritis. 
Only in the study group was PEG-precipitable TSH (%) 
found to be negatively (P=0.03) correlated with fT4 concentra-
tion (Fig. 3). In neither group was any correlation found be-
tween PEG-precipitable TSH (%) and age, sex, body mass in-
dex, years since thyroidectomy, tumor stage, radioiodine thera-
py, Tg levels, TgAb status, b.w.-related LT4 dosage, other con-
comitant drugs or TSH levels.
DISCUSSION
The prevalence of macro-prolactin in patients with hyperprolac-
tinemia ranges about from 10% to 30%, and it has been reported 
that this variability is dependent on the immunoassay platforms 
used [21]. The prevalence of mTSH is not well known. Macro-
TSH seems to be a heterogeneous entity which can be suspected 
when normal fT4 levels are associated to elevated TSH levels, 
and when substances that commonly interfere with TSH assays, 
including heterophilic antibodies, human anti-mouse/animal an-
tibodies (HAMA) and rheumatoid factors have been excluded 
[22]. Macro-TSH can also occur in patients with TSH concen-
trations within reference ranges [23]. To date, the bulk of data 
on mTSH prevalence have been provided by studies by Hattori 
et al. [17-19]. On searching for mTSH in 681 sera from patients 
with subclinical hypothyroidism, and using a cut-off of PEG-
precipitable TSH greater than 75%, these authors found a preva-
lence of mTSH of 1.6% after gel-filtration [17]. Subsequently, 
in 1901 sera from subclinical hypothyroidism patients, in which 
the presence of HAMA had been excluded, the prevalence of 
mTSH decreased to 0.8% [18]. A similar prevalence (0.6%) was 
reported by Mills et al. [24] in a study conducted on 495 sera 
with TSH levels above 10 mIU/L. 
No data on cohorts of thyroidectomy patients are available. In 
our study, PEG-precipitable TSH was 39.3%±1.9% in patients 
who had undergone total thyroidectomy for thyroid cancer and 
44.1%±3.9% in similarly treated patients with a final histologi-
cal diagnosis of benignity. These percentages seem to be some-
what lower than those reported in 681 samples from subjects 
with a clinical diagnosis of subclinical hypothyroidism (from 
21% to 100%; on average, 63%) [17] and in 10 samples from 
subjects with presumably normal thyroid function (from 58% to 
79%) [15]. On the other hand, mTSH distribution seems to be 
quite normal in our sera, as in the study by Hattori et al. [17]. In 





















Fig. 2. Distribution of polyethylene glycol (PEG)-precipitable thy-














  20 40 60 80 100
Fig. 3. Correlation between free-T4 (fT4) levels and polyethylene 
glycol (PEG)-precipitable thyrotropin (TSH) ratio (%) in the study 
group (n=74; Spearman correlation coefficient, –0.25; P=0.03). 
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the prevalence of mTSH (3.1%) was higher than that reported in 
subclinical hypothyroidism [17,18,24]. It is not clear whether 
this difference is due to the different cohort of patients or to the 
lack, in our study, of gel-filtration or HAMA examinations. 
However, the significant negative correlation seen between 
TSH after PEG-precipitable evaluation and fT4 concentrations 
in the study group, but not between TSH and fT4 levels before 
PEG precipitation, indicates that, in some patients, LT4 is not 
adequately titrated in relation to both elevated free-TSH and 
fT4. Literature data indicate that there is an increased need for 
LT4 in post-thyroidectomy patients, and that a wide range of 
daily LT4 regimens are available [25,26]. This increase has been 
ascribed to the need to replace direct glandular triiodothyronine 
production, which is no longer available in post-surgical hypo-
thyroid patients. Our data demonstrate that, in assessing the ad-
equacy of LT4 dosage after total thyroidectomy in thyroid can-
cer patients, the individual balance of fT4 and mTSH must also 
be considered.
In their review of published case reports, Loh et al. [15] re-
ported that the majority of patients with mTSH were females 
without symptoms of thyroid disorders, except for one with 
clinical features of hyperthyroidism. Hattori et al. [18] stated 
that mTSH is predominant in samples from elderly patients and 
that autoimmune mechanisms might be involved in the genera-
tion of mTSH [17]. On the other hand, some patients with 
mTSH have anti-Tg, anti-TSH receptors, and anti-thyroperoxi-
dase antibodies [15]. Although our population consisted of mid-
dle-aged and elderly patients, no correlation was noted between 
mTSH and age or TgAb status. Moreover, no correlation was 
found in the study group between mTSH and disease stage or 
previous radioiodine therapy. In our opinion, more data are 
needed in order to attribute mTSH generation to age, sex, or au-
toimmunity.
It has been suggested the screening for TSH in subclinical hy-
pothyroidism is necessary before LT4 therapy is initiated 
[17,18]. However, this seems routinely impracticable; the same 
can probably be said in the case of thyroid cancer patients. 
Moreover, the detection of mTSH must be undertaken in partic-
ular conditions in surgical hypothyroid patients (present data), 
such as in patients with sleep disorders [20]. 
Our study has several limitations: (1) both the study and con-
trol groups comprised few subjects; (2) no other laboratory pro-
cedures were performed after PEG-precipitation; (3) TSH was 
assayed by means of only one analytical platform; and (4) the 
cut-off of PEG-precipitable TSH was set arbitrarily.
In conclusion, free-TSH levels after PEG precipitation are on 
average 40% lower than serum TSH levels in hypothyroid sub-
jects with or without a history of thyroid carcinoma. The pres-
ence of mTSH seems to be a rare phenomenon in our patients. 
Patients suspected of having mTSH must be followed up for a 
long time, owing to the hypothesized long persistence of the im-
munoglobulin G-TSH complex [19]. In some patients with low 
PEG-precipitable TSH (%), a reduction in LT4 dosage could be 
suggested. Moreover, LT4 dosage adjusted to b.w. is the main 
factor in maintaining TSH in a semi-suppressed or normal range. 
More serum samples need to be evaluated in order to strike a 
balance between adequate TSH suppression and the avoidance 
of unnecessary long-term exogenous hyperthyroxinemia.
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